Premium
Intravitreal ranibizumab treatment of retinal angiomatous proliferation
Author(s) -
Kramann Christina A.,
Schöpfer Kilian,
Lorenz Katrin,
Zwiener Isabella,
Stoffelns Bernhard M.,
Pfeiffer Norbert
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.01952.x
Subject(s) - ranibizumab , medicine , visual acuity , ophthalmology , retinal , macular degeneration , foveal , surgery , bevacizumab , chemotherapy
. Purpose: To determine the efficacy of intravitreal injections of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) in neovascular age‐related macular degeneration. Methods: Retrospective, consecutive case series of 26 eyes (26 patients) treated with intravitreal injections of 0.5 mg ranibizumab for RAP. Patients received intravitreal injections at monthly intervals during upload phase for a 3‐month period. Results: Mean visual acuity before treatment was 0.75 ± 0.38logMAR (mean ± SD, n = 26). In the upload phase, mean visual acuity improved 4 weeks after the initial injection to 0.6 ± 0.37logMAR ( n = 26) and to 0.53 ± 0.34logMAR ( n = 26) 4 weeks after the third monthly intravitreal injection of ranibizumab. The mean optical coherence tomography (OCT) central foveal thickness reduced from 345 ± 55 μm at baseline to 215 ± 87 μm at 3 months. In the maintenance phase, mean visual acuity after 6 months was 0.66 ± 0.38logMAR ( n = 12) and 0.7 ± 0.37logMAR after 9 months ( n = 6). The mean OCT central foveal thickness was 259 ± 59 μm ( n = 13) at 6 months and 280 ± 127 μm ( n = 6) at nine‐month follow‐up. Conclusion: Intravitreal ranibizumab resulted in an improvement of visual acuity 4 weeks after the first injection but was more pronounced after 3 months. A reduction in leakage and OCT central foveal thickness was seen 3 months after the commencement of treatment.